Herantis Pharma Plc ("Herantis" or the "Company"), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease, has carried out an offering of new shares (the "New Shares") in a directed share issue to institutional and other qualified investors (the "Directed Issue"). Herantis raises gross proceeds of EUR 4.51 million in the Directed Issue.

The Company expects to issue a total of 3,219,139 New Shares in the Directed Issue, representing approximately 19 per cent of all issued shares prior to the Directed Issue and approximately 16 per cent of all issued shares following the Directed Issue. The total number of issued shares in the Company after the Directed Issue will be 20,160,733.

The subscription price is EUR 1.40 per New Share, corresponding to a discount of approximately 16 per cent to the closing price on Nasdaq First North Growth Market Finland on 5 December 2023. The subscription price shall be recorded in the invested unrestricted equity reserve.

The CEO of Herantis, Antti Vuolanto, comments: "We thank our existing shareholders, many of whom participated in this directed issue, for their continued support in developing HER-096 as a promising disease-modifying drug candidate for Parkinson’s disease. We are delighted to welcome the new investors and especially EIC Fund (European Innovation Council Fund) as new shareholders of the company."

The Directed Issue was based on the authorization given to the board of directors by the Company’s extraordinary general meeting of 17 November 2023.

Most of the New Shares (ISIN code FI4000087861) will be registered with the trade register maintained by the Finnish Patent and Registration Office on or about 8 December 2023 and they are expected to be ready for delivery to the investors through Euroclear Finland Ltd on or about 11 December 2023. The remainder of the New Shares are expected to be registered with the trade register and to be delivered to EIC Fund later in December 2023.

Herantis intends to make applications for the admission into trading of the New Shares on Nasdaq First North Growth Market Finland. Trading in most of the New Shares is expected to commence on Nasdaq First North Growth Market Finland on or about 12 December 2023 with the remaining New Shares to be listed shortly thereafter, subject to the respective listing applications being approved.

UB Securities Ltd is acting as the lead manager of the Directed Issue. Krogerus Attorneys Ltd is acting as the legal counsel to the Company.

Herantis Pharma Plc
The Board of Directors

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel.: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Us

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com